Np mrd loader

Record Information
Version2.0
Created at2024-09-10 19:02:21 UTC
Updated at2024-09-10 19:02:22 UTC
NP-MRD IDNP0334589
Secondary Accession NumbersNone
Natural Product Identification
Common NameEscitalopram
DescriptionEscitalopram, also known as esertia or cipralex, belongs to the class of organic compounds known as phenylbutylamines. Phenylbutylamines are compounds containing a phenylbutylamine moiety, which consists of a phenyl group substituted at the fourth carbon by an butan-1-amine. Escitalopram is a very strong basic compound (based on its pKa). In humans, escitalopram is involved in escitalopram action pathway. Escitalopram is a potentially toxic compound. Escitalopram was first documented in 2003 (PMID: 14501259). A 1--1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile that has S-configuration at the chiral centre (PMID: 14594439) (PMID: 14708881) (PMID: 15200745) (PMID: 15609164).
Structure
Thumb
Synonyms
ValueSource
(+)-CitalopramChEBI
(S)-CitalopramChEBI
EscitalopramumChEBI
EsertiaChEBI
S(+)-CitalopramChEBI
S-(+)-CitalopramChEBI
CipralexHMDB
LexaproHMDB
CytalopramHMDB
CitalopramHMDB
CelexaHMDB
Citalopram hydrobromideHMDB
Escitalopram oxalateHMDB
SeropramHMDB
Chemical FormulaC20H21FN2O
Average Mass324.3919 Da
Monoisotopic Mass324.16379 Da
IUPAC Name(1S)-1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile
Traditional Namelexapro
CAS Registry NumberNot Available
SMILES
CN(C)CCC[C@]1(OCC2=C1C=CC(=C2)C#N)C1=CC=C(F)C=C1
InChI Identifier
InChI=1S/C20H21FN2O/c1-23(2)11-3-10-20(17-5-7-18(21)8-6-17)19-9-4-15(13-22)12-16(19)14-24-20/h4-9,12H,3,10-11,14H2,1-2H3/t20-/m0/s1
InChI KeyWSEQXVZVJXJVFP-FQEVSTJZSA-N
Experimental Spectra
Not Available
Predicted Spectra
Not Available
Chemical Shift Submissions
Not Available
Species
Species of OriginNot Available
Chemical Taxonomy
Description Belongs to the class of organic compounds known as phenylbutylamines. Phenylbutylamines are compounds containing a phenylbutylamine moiety, which consists of a phenyl group substituted at the fourth carbon by an butan-1-amine.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassPhenylbutylamines
Direct ParentPhenylbutylamines
Alternative Parents
Substituents
  • Phenylbutylamine
  • Isocoumaran
  • Fluorobenzene
  • Halobenzene
  • Aralkylamine
  • Aryl halide
  • Aryl fluoride
  • Tertiary amine
  • Tertiary aliphatic amine
  • Oxacycle
  • Dialkyl ether
  • Ether
  • Carbonitrile
  • Nitrile
  • Organoheterocyclic compound
  • Organic oxygen compound
  • Organopnictogen compound
  • Amine
  • Organohalogen compound
  • Organofluoride
  • Organonitrogen compound
  • Organooxygen compound
  • Organic nitrogen compound
  • Hydrocarbon derivative
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors
  • 1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile (CHEBI:36791 )
Physical Properties
StateNot Available
Experimental Properties
PropertyValueReference
Melting PointNot AvailableNot Available
Boiling PointNot AvailableNot Available
Water SolubilityNot AvailableNot Available
LogPNot AvailableNot Available
Predicted Properties
PropertyValueSource
logP3.58ALOGPS
logP3.76ChemAxon
logS-4.7ALOGPS
pKa (Strongest Basic)9.78ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area36.26 ŲChemAxon
Rotatable Bond Count5ChemAxon
Refractivity94.02 m³·mol⁻¹ChemAxon
Polarizability35.21 ųChemAxon
Number of Rings3ChemAxon
BioavailabilityYesChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
HMDB IDHMDB0005028
DrugBank IDDB01175
Phenol Explorer Compound IDNot Available
FoodDB IDFDB023596
KNApSAcK IDNot Available
Chemspider ID129277
KEGG Compound IDNot Available
BioCyc IDNot Available
BiGG IDNot Available
Wikipedia LinkEscitalopram
METLIN IDNot Available
PubChem Compound146570
PDB IDNot Available
ChEBI ID36791
Good Scents IDNot Available
References
General References
  1. Sanchez C, Gruca P, Papp M: R-citalopram counteracts the antidepressant-like effect of escitalopram in a rat chronic mild stress model. Behav Pharmacol. 2003 Sep;14(5-6):465-70. doi: 10.1097/01.fbp.0000087733.21047.60. [PubMed:14501259 ]
  2. Croom KF, Plosker GL: Escitalopram: a pharmacoeconomic review of its use in depression. Pharmacoeconomics. 2003;21(16):1185-209. doi: 10.2165/00019053-200321160-00004. [PubMed:14594439 ]
  3. Gutteck U, Rentsch KM: Therapeutic drug monitoring of 13 antidepressant and five neuroleptic drugs in serum with liquid chromatography-electrospray ionization mass spectrometry. Clin Chem Lab Med. 2003 Dec;41(12):1571-9. doi: 10.1515/CCLM.2003.240. [PubMed:14708881 ]
  4. Hemels ME, Kasper S, Walter E, Einarson TR: Cost-effectiveness analysis of escitalopram: a new SSRI in the first-line treatment of major depressive disorder in Austria. Curr Med Res Opin. 2004 Jun;20(6):869-78. doi: 10.1185/030079904125003737. [PubMed:15200745 ]
  5. Francois C, Toumi M, Aakhus AM, Hansen K: A pharmacoeconomic evaluation of escitalopram, a new selective serotonin reuptake inhibitor. Comparison of cost-effectiveness between escitalopram, citalopram, fluoxetine, and venlafaxine for the treatment of depression in Norway. Eur J Health Econ. 2003;4(1):12-9. doi: 10.1007/s10198-002-0139-0. [PubMed:15609164 ]